October 01, 2019
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Santen announces positive 24-week data on Ikervis
Interim data from the PERSPECTIVE study showed statistically significant improvements in patients with severe keratitis who were treated with Ikervis, Santen announced in a press release.
Ikervis (cyclosporine A 0.1% eye drop emulsion) was effective, well tolerated and safe in dry eye and severe keratitis patients at 24 weeks, the release said.
Corneal fluorescein staining grade significantly improved by 77.4% at week 24, while tear breakup time also showed significant improvements.
Treatment-related adverse events were mostly localized at the administration site, and 67.7% were recovered without issue, the release said.